A Phase III Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP).

Trial Profile

A Phase III Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP).

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs MMR-varicella zoster virus vaccine (Primary)
  • Indications Measles; Mumps; Rubella; Varicella zoster virus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 11 Feb 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 30 Apr 2013 Planned End Date changed from 1 Feb 2014 to 1 Jan 2014 as reported by ClinicalTrials.gov.
    • 30 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top